Vimarsana
Biggest News Aggregation in the World

Page 35 - Beigene News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Beigene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Beigene Today - Breaking & Trending Today

Novartis tislelizumab plus chemotherapy significantly improved overall survival as first-line treatment for advanced esophageal cancer in Phase III study - Vimarsana News

Novartis tislelizumab plus chemotherapy significantly improved overall survival as first-line treatment for advanced esophageal cancer in Phase III study

RATIONALE 306 trial met primary endpoint at interim analysis, demonstrating tislelizumab plus chemotherapy significantly improved overall survival compared to chemotherapy alone in patients with previously untreated advanced esophageal squamous cell carcinoma (ESCC) 1

Global Phase 3 Trial of BeiGene's PD-1 Inhibitor, Tislelizumab, in Combination with Chemotherapy Meets Primary Endpoint in First-Line Advanced Esophageal Squamous Cell Carcinoma - Vimarsana News

Global Phase 3 Trial of BeiGene's PD-1 Inhibitor, Tislelizumab, in Combination with Chemotherapy Meets Primary Endpoint in First-Line Advanced Esophageal Squamous Cell Carcinoma

Statistically significant and clinically meaningful improvement in overall survival achieved for tislelizumab and chemotherapy compared to placebo and chemotherapy Safety profile for the

Analysts Anticipate BeiGene, Ltd. (NASDAQ:BGNE) Will Announce Quarterly Sales of $251.05 Million - Vimarsana News

Analysts Anticipate BeiGene, Ltd. (NASDAQ:BGNE) Will Announce Quarterly Sales of $251.05 Million

Equities analysts predict that BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) will report sales of $251.05 million for the current quarter, according to Zacks. Two analysts have provided estimates for BeiGene’s earnings. The highest sales estimate is $287.60 million and the lowest is $214.50 million. BeiGene reported sales of $605.87 million during the same quarter last […]

BeiGene, Ltd. (NASDAQ:BGNE) Given Average Recommendation of "Hold" by Analysts - Vimarsana News

BeiGene, Ltd. (NASDAQ:BGNE) Given Average Recommendation of "Hold" by Analysts

Shares of BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) have been given a consensus recommendation of “Hold” by the eight ratings firms that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the […]

Fierce Pharma Asia—Merck's former China head returns - Vimarsana News

Fierce Pharma Asia—Merck's former China head returns

Merck's former China head will return to the Big Pharma to lead international human health operations after a short stint at a Chinese company.